Cas 137281-39-1 Bulk Price Global Manufacturer 2026
- Technical Specification: High purity CAS 137281-39-1 suitable for oncology intermediate synthesis and antifolate precursor applications.
- Commercial Availability: Bulk pricing tiers available for industrial scale procurement with full COA and technical support.
- Logistics: Global shipping via express courier or freight with strict B2B compliance and quality assurance protocols.
The pharmaceutical landscape for oncology therapeutics continues to evolve, driving significant demand for high-quality key starting materials and advanced intermediates. Among these, CAS 137281-39-1 stands out as a critical component in the production of antifolate agents used in chemotherapy regimens. As we approach 2026, procurement managers and process chemists require reliable data on bulk pricing, synthesis scalability, and regulatory compliance. NINGBO INNO PHARMCHEM CO.,LTD. positions itself as a premier global manufacturer capable of meeting these rigorous demands through optimized manufacturing processes and consistent supply chain management.
This compound, chemically known as 4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid, serves as a vital Pemetrexed intermediate. The stability and purity of this molecule directly impact the yield and safety profile of the final active pharmaceutical ingredient (API). Consequently, sourcing from a vendor with established GMP standards and robust quality control systems is not merely a preference but a regulatory necessity. Our facility employs advanced analytical techniques to ensure every batch meets the stringent specifications required for downstream pharmaceutical synthesis.
Bulk Pricing Tiers and MOQ
Pricing for specialized oncology intermediates is influenced by several factors, including raw material costs, synthesis complexity, and order volume. Unlike commodity chemicals, the production of CAS 137281-39-1 involves multi-step organic synthesis requiring precise control over reaction conditions to minimize impurities. Therefore, bulk pricing is structured to reflect the value of industrial purity and the technical expertise embedded in the manufacturing process.
For procurement planning, buyers should anticipate tiered pricing structures that reward larger volume commitments. Minimum Order Quantities (MOQ) are typically set to ensure economic viability for production runs while maintaining flexibility for R&D scaling. Below is a representative table outlining typical commercial tiers for 2026:
| Order Volume | Purity Grade | Packaging | Lead Time |
|---|---|---|---|
| 1 kg - 5 kg | 98.0%+ (HPLC) | Double PE bag + Foil bag | 3-5 Days |
| 10 kg - 50 kg | 99.0%+ (HPLC) | Drum or Carton | 7-10 Days |
| 100 kg+ | 99.5%+ (HPLC) | Custom Industrial Packaging | 15-20 Days |
It is important to note that prices are subject to fluctuation based on global raw material availability and currency exchange rates. However, establishing a long-term contract with a reliable supplier mitigates volatility. When sourcing high-purity Pemetrexed free acid, buyers should request detailed quotations that include transparency on impurity profiles and residual solvent data. Our commercial team provides customized quotes that align with your specific production timelines and budgetary constraints.
Global Logistics and Lead Times
Efficient logistics are paramount in the pharmaceutical supply chain to prevent production delays. As a dedicated manufacturer, we utilize established international courier services such as FedEx, UPS, and DHL for smaller shipments, ensuring rapid delivery to research laboratories and pilot plants. For bulk industrial orders, freight forwarding via sea or air cargo is coordinated to optimize cost and delivery speed. All shipments are backed with full quality assurance documentation, including Safety Data Sheets (SDS) and Certificates of Analysis (COA).
Compliance with international shipping regulations is strictly enforced. Products are explicitly intended for research and development use or further pharmaceutical manufacturing by technically qualified persons. We adhere to a strict B2B model; consequently, products are not sold to individuals, and shipments to residential addresses are not permitted. New customers undergo an internal onboarding process to verify business legitimacy and ensure compliance with local regulatory frameworks. This may involve requesting additional documentation regarding the end-use of the materials.
Our logistics network ensures that whether you are located in Europe, Asia, or the Americas, your order arrives securely. Packaging is designed to protect the integrity of the chemical against moisture and light during transit. For time-sensitive projects, expedited shipping options are available upon request. The goal is to provide a seamless procurement experience that allows process chemists to focus on synthesis optimization rather than supply chain hurdles.
2026 Market Supply Trends
Looking toward 2026, the market for antifolate precursors is expected to grow in tandem with the increasing prevalence of cancer treatments requiring folate antagonists. The synthesis route for CAS 137281-39-1 is undergoing continuous improvement to enhance atom economy and reduce environmental impact. Manufacturers investing in greener chemistry and continuous flow processing are likely to dominate the supply landscape, offering better pricing and higher consistency.
Supply chain resilience remains a top priority for pharmaceutical companies. Diversifying sourcing strategies to include reliable partners in China is a common tactic to mitigate geopolitical risks and ensure continuity. NINGBO INNO PHARMCHEM CO.,LTD. maintains robust inventory levels and flexible production capacity to accommodate sudden spikes in demand. We understand that interruptions in the supply of critical intermediates can halt entire production lines, which is why our operational focus is on reliability and transparency.
Furthermore, regulatory scrutiny is intensifying regarding the documentation of raw materials. Buyers should expect stricter requirements for DMF (Drug Master File) support and audit readiness. Our facility is prepared to support customers with necessary technical documentation to facilitate regulatory filings. By partnering with a manufacturer that prioritizes technical support and regulatory compliance, pharmaceutical companies can accelerate their time-to-market for new oncology therapies.
Conclusion
Securing a stable supply of CAS 137281-39-1 is essential for the continued development and production of life-saving oncology medications. With a focus on industrial purity, scalable manufacturing processes, and global logistics capabilities, we are equipped to support your procurement needs through 2026 and beyond. For detailed specifications, current bulk pricing, or to initiate the onboarding process, contact our sales team today. Trust in a partner that combines chemical expertise with commercial reliability to drive your pharmaceutical projects forward.